Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michele Guida

Showing results (61-70 of 129) with videos related to

Pageof 13
Sort By:
Journal of Translational Medicine|November 30, 2011
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanomaOmid Hamid, Henrik Schmidt, Aviram Nissan, et al.
Scientific Reports|November 27, 2022
A deep learning model based on whole slide images to predict disease-free survival in cutaneous melanoma patientsMaria Colomba Comes, Livia Fucci, Fabio Mele, et al.
Dermatology (Basel, Switzerland)|June 6, 2013
Diagnostic and therapeutic approaches in Italian hospitals: adjuvant and metastatic therapy in melanomaVanna Chiarion-Sileni, Michele Guida, Antonella Romanini, et al.
Frontiers in Cell and Developmental Biology|June 29, 2023
Cervical cancer benefits from trabectedin combination with the β-blocker propranolol: <i>in vitro</i> and <i>ex vivo</i> evaluations in patient-derived organoidsRoberta Di Fonte, Sabino Strippoli, Marianna Garofoli, et al.
BMC Cancer|March 1, 2006
Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI - Mel.A.) [ISRCTN75125874]Vanna Chiarion-Sileni, Paola Del Bianco, Antonella Romanini, et al.
Frontiers in Molecular Biosciences|March 22, 2021
The Genetic Germline Background of Single and Multiple Primary MelanomasSimona De Summa, Antonia Lasorella, Sabino Strippoli, et al.
Frontiers in Oncology|October 4, 2021
Electrochemotherapy as a Trigger to Overcome Primary Resistance to Anti-PD-1 Treatment: A Case Report of Melanoma of the ScalpDavide Quaresmini, Alessandra Di Lauro, Livia Fucci, et al.
Cells|March 6, 2021
Examining the Relationship between Circulating CD4- CD8- Double-Negative T Cells and Outcomes of Immuno-Checkpoint Inhibitor Therapy-Looking for Biomarkers and Therapeutic Targets in Metastatic MelanomaSabino Strippoli, Annarita Fanizzi, Antonio Negri, et al.
Journal of Experimental & Clinical Cancer Research : CR|February 5, 2025
Developing a risk score using liquid biopsy biomarkers for selecting Immunotherapy responders and stratifying disease progression risk in metastatic melanoma patientsAmalia Azzariti, Simona De Summa, Tommaso M Marvulli, et al.
Journal of Translational Medicine|January 13, 2019
Translational control mechanisms in cutaneous malignant melanoma: the role of eIF2αImmacolata Maida, Paola Zanna, Stefania Guida, et al.
Pageof 13

Showing results (61-70 of 129) with videos related to

Sort By:
Pageof 13
Journal of Translational Medicine|November 30, 2011
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanomaOmid Hamid, Henrik Schmidt, Aviram Nissan, et al.
Scientific Reports|November 27, 2022
A deep learning model based on whole slide images to predict disease-free survival in cutaneous melanoma patientsMaria Colomba Comes, Livia Fucci, Fabio Mele, et al.
Dermatology (Basel, Switzerland)|June 6, 2013
Diagnostic and therapeutic approaches in Italian hospitals: adjuvant and metastatic therapy in melanomaVanna Chiarion-Sileni, Michele Guida, Antonella Romanini, et al.
Frontiers in Cell and Developmental Biology|June 29, 2023
Cervical cancer benefits from trabectedin combination with the β-blocker propranolol: <i>in vitro</i> and <i>ex vivo</i> evaluations in patient-derived organoidsRoberta Di Fonte, Sabino Strippoli, Marianna Garofoli, et al.
BMC Cancer|March 1, 2006
Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI - Mel.A.) [ISRCTN75125874]Vanna Chiarion-Sileni, Paola Del Bianco, Antonella Romanini, et al.
Frontiers in Molecular Biosciences|March 22, 2021
The Genetic Germline Background of Single and Multiple Primary MelanomasSimona De Summa, Antonia Lasorella, Sabino Strippoli, et al.
Frontiers in Oncology|October 4, 2021
Electrochemotherapy as a Trigger to Overcome Primary Resistance to Anti-PD-1 Treatment: A Case Report of Melanoma of the ScalpDavide Quaresmini, Alessandra Di Lauro, Livia Fucci, et al.
Cells|March 6, 2021
Examining the Relationship between Circulating CD4- CD8- Double-Negative T Cells and Outcomes of Immuno-Checkpoint Inhibitor Therapy-Looking for Biomarkers and Therapeutic Targets in Metastatic MelanomaSabino Strippoli, Annarita Fanizzi, Antonio Negri, et al.
Journal of Experimental & Clinical Cancer Research : CR|February 5, 2025
Developing a risk score using liquid biopsy biomarkers for selecting Immunotherapy responders and stratifying disease progression risk in metastatic melanoma patientsAmalia Azzariti, Simona De Summa, Tommaso M Marvulli, et al.
Journal of Translational Medicine|January 13, 2019
Translational control mechanisms in cutaneous malignant melanoma: the role of eIF2αImmacolata Maida, Paola Zanna, Stefania Guida, et al.
Pageof 13